Document Detail


Evaluation of patient expectations and treatment satisfaction after 1-year tadalafil therapy for erectile dysfunction: the DETECT study.
MedLine Citation:
PMID:  19170854     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
INTRODUCTION: Erectile dysfunction (ED) is a self-reported condition and satisfaction with sexual performance is individual, subjective, and multi-factorial. Treatment success depends on several outcomes. Tadalafil is a long-acting, selective inhibitor of phosphodiesterase 5 that has been shown to be effective at treating men with ED. AIM: To investigate patient's ED treatment expectations at baseline; patient satisfaction with tadalafil treatment after 12 months; factors associated with satisfaction; and effect of early tadalafil treatment satisfaction on tadalafil continuation at 12 months. METHODS: The Determinants of Continued Use of Tadalafil study is a 12-month, prospective, pan-European, noninterventional, observational study, which enrolled 1,900 patients with ED wishing to initiate or change their treatment to tadalafil. Assessments were made on predefined treatment outcomes in a routine clinical setting. MAIN OUTCOME MEASURES: International Index of Erectile Function-erectile function domain scores (at baseline, 1, 6, and 12 month visit), ED Inventory of Treatment Satisfaction (EDITS) scores (after 1, 6, and 12 months), and patient expectation questionnaire (at baseline visit) were analyzed for these patients. RESULTS: Data were available from 1,567 patients (82%) after 12 months, with similar baseline characteristics as the initial cohort. Treatment expectations identified as important included: erection hardness and ability to maintain erection through intercourse completion (>92% of patients); confidence, partner satisfaction, and naturalness (>84% of patients); rapid effect and long duration of treatment (>75% of patients). Continued tadalafil use from 1,319 (84%) patients at 12 months were reported. Total EDITS scores for those continuing treatment was 85.9 (95% CI: 85.1-86.7). Increased satisfaction was associated with higher effectiveness, number of sexual attempts, partner support, good relationships, and good drug tolerance. Treatment satisfaction at 1 month was best predictive of treatment continuation at 12 months. CONCLUSIONS: Eighty-four percent of patients reported continued use of tadalafil after 12 months. High satisfaction after first month of treatment was the best predictor of treatment continuation.
Authors:
Petros Perimenis; Thierry Roumeguere; Helmut Heidler; Erik Roos; Mark Belger; Henry Schmitt
Related Documents :
19836164 - Gains from real-time tracking of prostate motion during external beam radiation therapy.
12386784 - High-dose rate brachytherapy of prostatic adenocarcinoma in combination with external b...
17899954 - Reduction of length of hospital stay after transurethral resection of prostate by early...
9186334 - The early postoperative morbidity of transurethral resection of the prostate and of 4 m...
8352714 - Radiofrequency catheter ablation for paroxysmal supraventricular tachycardia: a report ...
15728604 - Successful treatment of hepatocellular adenoma with percutaneous radiofrequency ablation.
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  The journal of sexual medicine     Volume:  6     ISSN:  1743-6109     ISO Abbreviation:  -     Publication Date:  2009 Jan 
Date Detail:
Created Date:  2009-01-27     Completed Date:  2009-07-13     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101230693     Medline TA:  J Sex Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  257-67     Citation Subset:  IM    
Affiliation:
University Hospital of Patras, Department of Urology, Patras, Greece. petperim@upatras.gr
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Attitude to Health*
Carbolines / therapeutic use*
Erectile Dysfunction / drug therapy*
Humans
Male
Middle Aged
Patient Satisfaction*
Phosphodiesterase Inhibitors / therapeutic use*
Prospective Studies
Questionnaires
Chemical
Reg. No./Substance:
0/Carbolines; 0/Phosphodiesterase Inhibitors; 0/tadalafil

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effects of intensive lifestyle changes on erectile dysfunction in men.
Next Document:  Serotonin transporter promoter region (5-HTTLPR) polymorphism is associated with the intravaginal ej...